Citigroup has issued a research report stating that RIBOLIFE-B (06938) is a leading enterprise in the siRNA field, possessing core advantages such as a differentiated drug pipeline and an advanced drug delivery technology platform. The bank believes that RIBOLIFE-B's core candidate drug, RBD4059, has the potential to become a breakthrough treatment for thrombotic diseases, with sales potential exceeding $6 billion, a potential which the market currently underestimates. Citigroup initiated coverage on the company with a "Buy" rating and a target price of HK$102.